miércoles, 19 de agosto de 2026
In wake of boy’s death, gene editing experts dissect Huidagene’s decisions Reaction veers from ‘not sure it was unreasonable to try’ to dismay over ‘garbage data’
https://www.statnews.com/2026/08/19/huidagene-clinical-trial-deaths-experts-dissect-study-design/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-_ZUeqSCkxSlql0x9OPhIztIiAd1mka1A9htgRNWMSb-zLrv9IYHfr_Kr2AWbFHUCAF4kRx27Zhz0kM_V13hx4oU7pdOQ&_hsmi=433874198&utm_content=433874198&utm_source=hs_email
By Jason MastAug. 19, 2026
General Assignment Reporter
Experts scrutinize Huidagene’s disclosures after patient death
Earlier this month, STAT reported that a child who received a gene therapy from the Chinese company Huidagene had died. In the wake of that death, my colleague Jason Mast asked experts to review Huidagene's prior disclosures, particularly a presentation it gave at a prominent scientific conference last year.
Reactions were mixed, but some experts highlighted several concerns with the data, with one saying the company put a “positive spin” on them.
It’s not clear whether the child's death could have been forseen, but these developments have heightened the debate about the quality and transparency of certain trials in China.
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial Results could herald a new, powerful approach in other cancers
https://www.statnews.com/2026/08/19/mrna-cancer-vaccine-trial-melanoma-merck-moderna/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz--Ib0xFLwMoh0sxuC5O3QRXH4wBV01pPZjpY2_GPXw_LUe9hvVnI2Rw5HHINhhoFmvR6UyMHgmENxg6EZFxlENtcmcb-A&_hsmi=433874198&utm_content=433874198&utm_source=hs_email
By Matthew Herper and Angus ChenAug. 19, 2026
Merck and Moderna's mRNA cancer vaccine succeeds in late-stage trial
Scientists have long hoped that personalized mRNA cancer vaccines could be the next big breakthrough in oncology treatment. Today, Merck and Moderna said they had shown in a randomized late-stage trial for the first time that such a drug can work.
For melanoma patients, the vaccine, called intismeran, combined with Merck’s Keytruda, extended the amount of time before their cancer came back and before new lesions appeared in other regions of their body.
The results suggest it's now possible to achieve “what might have been considered science fiction 15 or 20 years ago,” one oncologist said.
COVID-19 mortality gap between men and women narrowed sharply as the pandemic progressed
https://www.news-medical.net/news/20260819/COVID-19-mortality-gap-between-men-and-women-narrowed-sharply-as-the-pandemic-progressed.aspx
A 34-country analysis comparing absolute and relative excess deaths reveals how the apparent mortality divide between men and women shifted across successive stages of the COVID pandemic.
Suscribirse a:
Entradas (Atom)
.png)
